MP27-18 REZūm IN THE GOLDEN YEARS: REAL-WORLD FUNCTIONAL OUTCOMES IN MEN OLDER THAN 75 YEARS

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology II (MP27)1 May 2024MP27-18 REZūm IN THE GOLDEN YEARS: REAL-WORLD FUNCTIONAL OUTCOMES IN MEN OLDER THAN 75 YEARS Roseanne Ferreira, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, and Dean Elterman Roseanne FerreiraRoseanne Ferreira , Naeem BhojaniNaeem Bhojani , Bilal ChughtaiBilal Chughtai , Kevin C. ZornKevin C. Zorn , and Dean EltermanDean Elterman View All Author Informationhttps://doi.org/10.1097/01.JU.0001009400.86696.a2.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Managing lower urinary tract symptoms in elderly patients suffering from benign prostatic hyperplasia is a complex endeavor due to the limitations of pharmacological treatments and risks associated with invasive surgical procedures. Herein, we aim to assess the real-world functional outcomes of the Rezūm procedure in patients aged 75 and older. METHODS: We performed a comprehensive analysis of data from the Canadian Rezūm Registry, which includes two high-volume centers. The dataset comprises patients who underwent Rezūm treatment from 2019 to 2023 and were categorized into two age cohorts: below 75 years and 75 years or older. International Prostate Symptom Score (IPSS), Quality of Life (QoL), and maximum urinary flow rate (Qmax) were evaluated at baseline, 3- and 6-month follow-up. Descriptive statistics were analyzed using t-tests, Fisher's exact tests, or Mann-Whitney U tests. RESULTS: Out of 480 patients analyzed, data for 60 men aged over 75 and 210 men aged below 75 were available for up to a 6-month follow-up. Older patients exhibited significantly larger prostates (81.6 g vs. 71.5 g, p=0.01), lower baseline mean IPSS scores (20.6 vs. 22.4, p=0.03), and comparable prevalence of median lobes (63.6% vs. 67.4%, p=0.48). The proportion of patients achieving Minimal Clinically Important Difference (MCID) at 3 months (73.0% vs. 81.9%, p=0.152) and 6 months (82.7% vs. 87.6%, p=0.363) did not differ significantly between the two age groups. Functional outcomes between 75-year-old patients and younger patients were not significantly different at 3 and 6-month follow-up (Table 1). Furthermore, no significant change in IPSS, QoL, or Qmax from baseline were observed at any follow-up intervals between the age cohorts. CONCLUSIONS: Rezūm is a viable and safe treatment alternative for well-selected patients aged 75 and older. Our findings indicate no substantial differences in IPSS and QoL outcomes between elderly and younger patients at 6-month follow-up. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e430 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Roseanne Ferreira More articles by this author Naeem Bhojani More articles by this author Bilal Chughtai More articles by this author Kevin C. Zorn More articles by this author Dean Elterman More articles by this author Expand All Advertisement PDF downloadLoading ...